Bavarian Nordic A/S today announced the appointment of Henrik Juuel to the position of Executive Vice President and Chief Financial Officer. Mr. Juuel is currently the CFO of Orexo AB.
Nordic Nanovector ASA today announces that Rainer Boehm, MD was elected as a member of its Board of Directors at the companys Annual General Meeting on 30 May 2018.
Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).
Marc Wolff has been named Chief Financial Officer of Aldevron, a provider of plasmid DNA manufacturing, protein production and antibody discovery services. Mr. Wolff will lead the global finance and accounting team across all Aldevron sites in the U.S. and Europe.
Horizon Discovery Group plc has announced the appointment of Terry Pizzie as Chief Executive Officer and Board Director with immediate effect.
Bayer today announced the selection of the new Executive Leadership Team for the Crop Science division, which will go into effect as of the closing of Bayers proposed acquisition of Monsanto. The closing is still subject to pending regulatory approval.
Sonde Health Inc., an affiliate of PureTech Health (PureTech Health plc, PRTC.L) developing a voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, today announced that Thai Lee, President and Chief Executive Officer of SHI International Corporation, has joined Sondes Board of Directors.
Neurimmune today announced that it has appointed Dr. Fabian Buller to the newly created position Chief Business Officer. Dr. Buller joins Neurimmunes executive team and brings 8 years of professional experience with biotech and pharma companies.
Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Matilda Bingham as Site Director of its Alderley Park site in Cheshire, UK, and David Higton as Principal Scientist (Biotransformation and Metabolite Identification), also based at the Alderley Park site.
Redx Pharma announced today that it has appointed Lisa Anson as Chief Executive Officer (CEO) and to its Board of Directors. Lisa will take up both roles on 1 June 2018. At that time Iain Ross, currently Executive Chairman, will revert to being Non-Executive Chairman.